Literature DB >> 19422450

Biosimilar low molecular weight heparin products.

E Gray1, B Mulloy.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19422450     DOI: 10.1111/j.1538-7836.2009.03461.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  4 in total

1.  Biosimilars-why terminology matters.

Authors:  Martina Weise; Marie-Christine Bielsky; Karen De Smet; Falk Ehmann; Niklas Ekman; Gopalan Narayanan; Hans-Karl Heim; Esa Heinonen; Kowid Ho; Robin Thorpe; Camille Vleminckx; Meenu Wadhwa; Christian K Schneider
Journal:  Nat Biotechnol       Date:  2011-08-05       Impact factor: 54.908

2.  Complete Molecular Weight Profiling of Low-Molecular Weight Heparins Using Size Exclusion Chromatography-Ion Suppressor-High-Resolution Mass Spectrometry.

Authors:  Joseph Zaia; Kshitij Khatri; Joshua Klein; Chun Shao; Yuewei Sheng; Rosa Viner
Journal:  Anal Chem       Date:  2016-10-17       Impact factor: 6.986

3.  Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism.

Authors:  Sake J van der Wall; Frederikus A Klok; Paul L den Exter; Deisy Barrios; Raquel Morillo; Suzanne C Cannegieter; David Jimenez; Menno V Huisman
Journal:  Hemasphere       Date:  2018-02-02

4.  Commercial Low Molecular Weight Heparins - Patent Ecosystem and Technology Paradigm for Quality Characterization.

Authors:  Zarina Iqbal; Saima Sadaf
Journal:  J Pharm Innov       Date:  2022-07-28       Impact factor: 2.538

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.